UPenn sues Genen­tech over patent in­fringe­ment with four can­cer drugs

4 years ago
Pharma

That par­tial hold on Gilead­'s $5B can­cer drug? It's worse than we were ini­tial­ly told

4 years ago
FDA+

Ab­b­Vie's Gon­za­lez: Skyrizi and Rin­voq to be­come Hu­mi­ra 2.0 — while adding an in­di­ca­tion for atopic der­mati­tis

4 years ago
R&D
Pharma

Vas Narasimhan re­veals a dis­ap­point­ing out­look for No­var­tis' gener­ics unit, while lay­ing out the phar­ma's M&A ...

4 years ago
Pharma

Point un­veils new In­dy site to shore up sup­ply chain in fight against prostate can­cer

4 years ago
Pharma
Manufacturing

PhRMA goes on the of­fen­sive, at­tack­ing the WHO and putting the EU, UK, Aus­tralia and oth­ers on no­tice

4 years ago
R&D
Pharma

Organon launch­es day-off cam­paign to en­cour­age busi­ness lead­ers to pri­or­i­tize wom­en's health

4 years ago
Pharma
Marketing

With new buy­out, J&J jumps back in on a sto­ried but trou­bled Holy Grail tar­get

4 years ago
Deals

4SC pulls plug on do­mati­no­s­tat; Pharm­ing says le­niolis­ib meets both end­points

4 years ago
News Briefing

Cash-strapped an­tibi­otics play­er En­ta­sis could go pri­vate with a small-dol­lar buy­out of­fer on the ta­ble

4 years ago
Deals

A faster 'pro­tein print­er' out of the UK earns new round of fund­ing with plans to ex­pand plat­form

4 years ago
Financing
Discovery

Carl June: ‘We can now con­clude that CAR-T cells can ac­tu­al­ly cure pa­tients’

4 years ago
R&D
Discovery

No­vo surges on up­beat Q4 re­view and a move to pro­duce We­govy in-house. But charge of in­sulin price ma­nip­u­la­tion ...

4 years ago
Pharma

FDA slams clin­i­cal hold on Log­icBio's gene edit­ing drug af­ter clot­ting cas­es in child pa­tients

4 years ago
Cell/Gene Tx
FDA+

A win in Rett syn­drome? Not so fast — biotech shares slide amid con­cerns of last-minute tri­al changes

4 years ago
R&D

GSK grabs $1.25B cash and a cut of Gilead­'s megablock­buster Bik­tarvy sales as HIV ri­vals set­tle patent suit

4 years ago
Pharma

No­var­tis ax­es a once 'first-in-class' prospect as an­oth­er JAK pro­gram fails to clear a risk/ben­e­fit analy­sis

4 years ago
R&D

FDA takes a rare step and asks Pfiz­er to sub­mit a Covid-19 vac­cine EUA for the youngest chil­dren

4 years ago
FDA+
Coronavirus

New buy­ers lin­ing up bids for No­var­tis' gi­ant gener­ics arm

4 years ago
Pharma

Re­ci­phar­m's glob­al deal spree con­tin­ues with ac­qui­si­tion of Por­tuguese CD­MO

4 years ago
Manufacturing

Af­ter deal shield­ing Sack­lers from fur­ther lit­i­ga­tion over­turned, fam­i­ly mem­bers to pour more mon­ey in­to set­tle­ment

4 years ago
Pharma

Up­dat­ed: Con­tro­ver­sial opi­oid Zo­hy­dro ER pulled from the mar­ket

4 years ago
R&D

Bak­er's dozen: Pfiz­er joins 12 peers in re­strict­ing sales of dis­count­ed drugs un­der a fed­er­al pro­gram

4 years ago
R&D

Pfiz­er raids Roche ex­ec­u­tive com­mit­tee for new drug de­vel­op­ment chief — and Schwan plucks his re­place­ment from the ...

4 years ago
People
Pharma
First page Previous page 581582583584585586587 Next page Last page
A service from the Financial Times